Trend in the Philippines

A total of 2,495 leptospirosis cases were reported nationwide from January 1 to December 2, 2017. This is 49.1% higher compared to the same time period last year (1,673).

Fig. 1 Reported Leptospirosis Cases by Morbidity Week
Philippines, as of January 1, 2017-December 2, 2017* (N=2,495)

Fig. 2 Reported Leptospirosis Cases by Region,
Philippines, as of January 1, 2017-December 2, 2017* (N=2,495)

*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.
Leptospirosis Cases

January 1, 2017-December 2, 2017
Public Health Surveillance Division

Fig. 3 Reported Leptospirosis Cases by Morbidity Week, Philippines, as of January 1, 2017-December 2, 2017*
2017 vs 2016 (N=2,495)

Geographic Distribution
Most of the cases were from the following regions: NCR (19.2%), REGION VI (19%), REGION I (14.8%), REGION III (8.3%) and REGION II (6.5%).

Fig. 4 Reported Leptospirosis Cases by Region, Philippines, 2017* vs 2016

*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.
Leptospirosis Cases

Profile of Cases

Ages of cases ranged from less than 1 to 82 years old (median = 30 years). Majority (88.4%) of cases were male. Most (15.4%) of the cases belonged to the age group of 15-19 years old (Fig. 5). There were 261 deaths (CFR = 10.46%). The 45-49 age group (Fig. 6) has the highest CFR (20%).

Fig. 5 Reported Leptospirosis Cases by Age Group and Sex
Philippines, as of January 1, 2017-December 2, 2017* (N=2,495)

Fig. 6 Reported Leptospirosis Case Fatality Rate (CFR) by Age Group, Philippines, as of January 1, 2017-December 2, 2017* (n=261)

*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.
### Table 1. Leptospirosis Cases & Deaths by Region
Philippines, 2017 vs 2016

<table>
<thead>
<tr>
<th>Region</th>
<th>Cases</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2017</td>
<td>2016</td>
</tr>
<tr>
<td>I</td>
<td>369</td>
<td>310</td>
</tr>
<tr>
<td>II</td>
<td>163</td>
<td>57</td>
</tr>
<tr>
<td>III</td>
<td>207</td>
<td>297</td>
</tr>
<tr>
<td>IV-A</td>
<td>94</td>
<td>130</td>
</tr>
<tr>
<td>IV-B</td>
<td>18</td>
<td>31</td>
</tr>
<tr>
<td>V</td>
<td>83</td>
<td>51</td>
</tr>
<tr>
<td>VI</td>
<td>474</td>
<td>181</td>
</tr>
<tr>
<td>VII</td>
<td>125</td>
<td>25</td>
</tr>
<tr>
<td>VIII</td>
<td>90</td>
<td>11</td>
</tr>
<tr>
<td>IX</td>
<td>34</td>
<td>18</td>
</tr>
<tr>
<td>X</td>
<td>81</td>
<td>53</td>
</tr>
<tr>
<td>XI</td>
<td>154</td>
<td>35</td>
</tr>
<tr>
<td>XII</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>ARMM</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>CAR</td>
<td>69</td>
<td>30</td>
</tr>
<tr>
<td>CARAGA</td>
<td>45</td>
<td>17</td>
</tr>
<tr>
<td>NCR</td>
<td>478</td>
<td>418</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2495</strong></td>
<td><strong>1673</strong></td>
</tr>
</tbody>
</table>

Figures 7-23. Leptospirosis Alert and Epidemic Thresholds per Region as of January 1-December 2, 2017*

Fig. 7 Reported Leptospirosis Cases by Morbidity Week
Region I, as of January 1-December 2, 2017 (n=369)

Fig. 8 Reported Leptospirosis Cases by Morbidity Week
Region II, as of January 1-December 2, 2017 (n=163)

*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.
Fig. 9 Reported Leptospirosis Cases by Morbidity Week Region III, as of January 1-December 2, 2017 (n=207)

Fig. 10 Reported Leptospirosis Cases by Morbidity Week Region IV-A, as of January 1-December 2, 2017 (n=94)

Fig. 11 Reported Leptospirosis Cases by Morbidity Week Region IV-B as of January 1-December 2, 2017 (n=18)

Fig. 12 Reported Leptospirosis Cases by Morbidity Week Region V, as of January 1-December 2, 2017 (n=83)

Fig. 13 Reported Leptospirosis Cases by Morbidity Week Region VI, as of January 1-December 2, 2017 (n=474)

Fig. 14 Reported Leptospirosis Cases by Morbidity Week Region VII, as of January 1-December 2, 2017 (n=125)

*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.
Fig. 15 Reported Leptospirosis Cases by Morbidity Week Region VIII, as of January 1-December 2, 2017 (n=90)

Fig. 16 Reported Leptospirosis Cases by Morbidity Week Region IX, as of January 1-December 2, 2017 (n=34)

Fig. 17 Reported Leptospirosis Cases by Morbidity Week Region X, as of January 1-December 2, 2017 (n=81)

Fig. 18 Reported Leptospirosis Cases by Morbidity Week Region XI, as of January 1-December 2, 2017 (n=154)

Fig. 19 Reported Leptospirosis Cases by Morbidity Week Region XII, as of January 1-December 2, 2017 (n=6)

Fig. 20 Reported Leptospirosis Cases by Morbidity Week ARMM, as of January 1-December 2, 2017 (n=5)

*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.
Fig. 21 Reported Leptospirosis Cases by Morbidity Week CAR, as of January 1-December 2, 2017 (n=69)

Fig. 22 Reported Leptospirosis Cases by Morbidity Week CARAGA, as of January 1-December 2, 2017 (n=45)

Fig. 23 Reported Leptospirosis Cases by Morbidity Week NCR, as of January 1-December 2, 2017 (n=478)

EDITORIAL BOARD

IRMA L. ASUNCION, MD, MHA, CESO IV
Director IV, Epidemiology Bureau

GENESIS MAY J. SAMONTE, MD, MSc, PHSAE
OIC, Division Chief PHSD

June Cantata B. Corpuz, RN
Nurse III

Jezza Jonah D. Crucena, RN
Nurse III

*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.